{"entity":{"id":"nct06797297","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastat","aka":[],"tldr":"A phase 2 trial of IBI363, Pembrolizumab in melanoma, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.","summary":"A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy is a phase 2 interventional study registered as NCT06797297 by Innovent Biologics (Suzhou) Co. Ltd., with 180 participants planned, started 2025-02-24 and due to reach its primary completion in 2026-03-31. Interventions recorded: IBI363, Pembrolizumab. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06797297","url":"https://clinicaltrials.gov/study/NCT06797297"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["ibi363","pembrolizumab"],"companies":["innovent"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06797297","phase":"2","setting":"A Phase II, Open-label, Randomized, Multi-center Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal and Acral Melanoma Who Had Not Previously Received Systemic Therapy","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","enrolled":180,"outcomes":[]},"route":"/trials/nct06797297/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"drug":[{"id":"ibi363","kind":"drug","name":"IBI363","route":"/drugs/ibi363/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"innovent","kind":"company","name":"Innovent Biologics","route":"/companies/innovent/"}]}}